CompletedNCT05932407

A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression

Observational studyJapan

The study in practice

Understand this study

Study clarity

Study start dateStarted: June 1, 2024

Recruitment status: Completed
Enrollment listed in the registry: 147,777
Sponsor: Takeda
Sponsor type: Unknown or unclear
Study type: Observational
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: Japan
Age range: Not clearly listed
Official registry ID: NCT05932407
Official title: Show the full official title
Post-marketing Database Survey: A Cohort Study of Comparison the Risk of Haemorrhage (Serious Intracranial Haemorrhage Such as Cerebral Haemorrhage and Subarachnoid Haemorrhage) Between Vortioxetine Tablets and SSRIs In Patients With Depression Using JMDC Claims Database

Completed

Tokyo

FAQ

Who is behind this study?

The study sponsor is Takeda.

Did this study involve medication?

Yes. The study involved medication, including Vortioxetine Tablet and SSRI.